GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK)
R&D Expense Growth
104.85%
Quarterly · Period ending:
GSK R&D Expense Growth
Latest reported104.85%period ending
Latest reported104.85%period ending
GSK Quarterly R&D Growth (QoQ) (0.00% → 104.85%)
Latest values, visible window
High-resolution chart · PNG
GSK r&d expense growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| 104.8463% | |
| -28% | |
| 39.1356% | |
| -16.5514% | |
| 38.4405% | |
| -28.0158% | |
| 39.2049% | |
| -1.2187% | |
| 2.9986% | |
| -29.9463% | |
| 29.9683% | |
| 17.4497% | |
| 6.4286% | |
| -29.8831% | |
| 33.5067% | |
| 8.3736% | |
| 12.602% | |
| -23.826% | |
| 2.2599% | |
| 21.3368% | |
| 4.3828% | |
| -23.9456% | |
| 28.9474% | |
| -12.3751% | |
| 9.604% | |
| -4.5052% | |
| 3.068% | |
| 8.3558% | |
| 10.6362% | |
| -6.5056% | |
| 8.9069% | |
| 6.8108% | |
| 2.323% | |
| -25.2275% | |
| 15.4728% | |
| -16.9048% | |
| 31.25% | |
| -4.2871% | |
| 8.7852% | |
| 3.8288% | |
| 8.9571% | |
| -22.6755% | |
| 27.4486% | |
| 1.8473% | |
| -6.3437% | |
| -11.4402% | |
| 21.9178% | |
| -0.7417% | |
| -5.8207% | |
| -19.7196% | |
| 18.8889% | |
| -14.204% | |
| 16.0398% | |
| -20.7713% | |
| 21.7716% | |
| 1.4069% | |
| -5.1335% | |
| -11.0502% | |
| 11.2805% | |
| -3.0542% | |
| 10.929% | |
| -16.5907% | |
| 9.2629% | |
| -16.0535% | |
| 3.1034% | |
| 2.9281% | |
| 27.7778% | |
| -9.3525% | |
| -13.4342% | |
| -7.2607% | |
| 39.4707% | |
| 5.9756% | |
| 5.1282% | |
| -18.4365% | |
| 24.3741% | |
| -2.5478% | |
| 8.6777% | |
| -25.8416% | |
| 12.3979% | |
| 2.0575% | |
| 13.4941% | |
| -22.2657% | |
| 20.468% | |
| 14.5263% | |
| 5.754% | |
| -15.7306% | |
| 13.0412% | |
| -0.0005% | |
| 5.6146% | |
| -19.4495% | |
| 20.1351% | |
| 5.1627% | |
| 1.1142% | |
| -29.234% | |
| 28.187% | |
| 13.3226% | |
| -6.4565% | |
| 2.0058% | |
| -0.6235% | |
| 0.1524% |